Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains

• Main Authors: Chia-Jung Kuo, Cheng-Yu Lin, Puo-Hsien Le, Pi-Yueh Chang, Chih-Ho Lai, Wey-Ran Lin, Ming-Ling Chang, Jun-Te Hsu, Hao-Tsai Cheng, Chi-Nan Tseng, Chun-Jung Lin, Ming-Yao Su, Sen-Yung Hsieh, Cheng-Tang Chiu
• Format: Article
• Language: English
• Published: BMC 2020-07-01
• Series: BMC Gastroenterology
• Online Access: http://link.springer.com/article/10.1186/s12876-020-01370-4

Abstract Background There is no current standard rescue treatment for dual drug-resistant strains of Helicobacter pylori (H. pylori). This aim of this study was to investigate the efficacy of rifabutin-based triple therapy for patients infected with dual drug-resistant strains to clarithromycin and levofloxacin. Methods After 2 or 3 H. pylori treatment failures, patients underwent upper endoscopy with tissue biopsies. Phenotypic and genotypic resistances were determined using agar dilution test and polymerase chain reaction with direct sequencing, respectively. Patients infected with dual drug-resistant (clarithromycin and levofloxacin) strains and receiving rifabutin-based triple therapy (rifabutin 150 mg bid, amoxicillin 1 g bid and esomeprazole 40 mg bid for 10 days) were enrolled. Eradication status was determined by 13C-urea breath test 4 weeks after treatment completion. Results A total of 39 patients infected with dual drug-resistant strains were enrolled in this study, with a mean age of 55.9 years. The eradication rate was 79.5% (31/39) (95% confidence intervals: 54.96% ~ 111.40%). Adverse event was reported in 23.1% (9/39) of patients but they were mild and tolerable. In univariate analysis, no factor was identified as an independent predictor of eradication failure. Conclusions Our current study demonstrated that rifabutin-based triple therapy was well tolerated and yielded an acceptable eradication rate for patients infected with dual drug-resistant strains of H. pylori.